Suppr超能文献

中国人群散发性甲状腺髓样癌中PD-L1表达、Ki-67指数及分子改变的临床意义与相互关系

Clinical significance and interrelations of PD-L1 expression, Ki-67 index, and molecular alterations in sporadic medullary thyroid carcinoma from a Chinese population.

作者信息

Bai Yanhua, Guo Ting, Niu Dongfeng, Zhu Yanli, Ren Wenhao, Yao Qian, Huang Xiaozheng, Feng Qin, Wang Tianxiao, Ma Xiuli, Ji Xinqiang

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.

Division of Gastrointestinal Cancer Translational Research Laboratory, Peking University Cancer Hospital & Institute, Beijing, China.

出版信息

Virchows Arch. 2022 Dec;481(6):903-911. doi: 10.1007/s00428-022-03390-9. Epub 2022 Aug 3.

Abstract

Immunotherapy shows prospects in treating advanced medullary thyroid carcinoma although controversial reports are present. Recently, histological grading has been applied to medullary thyroid carcinoma by the Ki-67 index, mitotic figures, and tumor necrosis. However, the interrelation of PD-L1 expression, the Ki-67 index, and major genetic alterations of sporadic medullary thyroid carcinoma has not been fully reported. We examined the expression of PD-L1 (SP142 and 22C3) and the Ki-67 index immunohistologically and detected the major genetic alterations by next-generation sequencing in a cohort of sporadic medullary thyroid carcinomas, studied their survival impact, and discussed their interrelation. We identified that a high Ki-67 index (> 2%) and positive RET M918T mutation were correlated with poor disease-free survival but were not correlated with PD-L1 expression. All PD-L1 positive tumors were RET M918T mutation negative, and PD-L1 expression was positively correlated with HRAS mutation. The Ki-67 index was correlated with neither PD-L1 expression nor major genetic alterations. Our results indicate that immunotherapy targeting PD-L1/PD-1 might be more effective for patients with sporadic medullary thyroid carcinoma harboring HRAS mutations.

摘要

尽管存在争议性报道,但免疫疗法在治疗晚期甲状腺髓样癌方面显示出前景。最近,通过Ki-67指数、有丝分裂象和肿瘤坏死情况对甲状腺髓样癌进行了组织学分级。然而,散发性甲状腺髓样癌的PD-L1表达、Ki-67指数与主要基因改变之间的相互关系尚未得到充分报道。我们通过免疫组织化学方法检测了散发性甲状腺髓样癌队列中PD-L1(SP142和22C3)的表达及Ki-67指数,并通过下一代测序检测了主要基因改变,研究了它们对生存的影响,并探讨了它们之间的相互关系。我们发现,高Ki-67指数(>2%)和RET M918T阳性突变与无病生存期差相关,但与PD-L1表达无关。所有PD-L1阳性肿瘤均为RET M918T突变阴性,且PD-L1表达与HRAS突变呈正相关。Ki-67指数与PD-L1表达及主要基因改变均无相关性。我们的结果表明,针对PD-L1/PD-1的免疫疗法可能对携带HRAS突变的散发性甲状腺髓样癌患者更有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验